metolazone has been researched along with Cardiac Failure in 36 studies
Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide." | 9.69 | Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. ( Brooksbank, KJM; Campbell, RT; Clark, AL; Docherty, KF; Foley, PWX; Guha, K; Halliday, CA; Jhund, PS; Kalra, PR; Lang, NN; Lee, MMY; McConnachie, A; McDermott, JJ; McKinley, G; McMurray, JJV; Osmanska, J; Petrie, MC; Platz, E; Sartipy, P; Seed, A; Stanley, B; Weir, RAP; Welsh, P; Yeoh, SE, 2023) |
| "To compare efficacy and safety of indapamide-furosemide combination against metolazone-furosemide combination in refractory heart failure patients." | 9.30 | Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial. ( Altaf, A; Jan, MU; Salahudin, M; Shah, H, 2019) |
| "17 patients with New York Heart Association (NYHA) class IV congestive cardiac failure, refractory to conventional treatment, were additionally treated with oral metolazone (1." | 9.06 | Metolazone in treatment of severe refractory congestive cardiac failure. ( Arter, WJ; Field, MJ; Kiyingi, A; Lawrence, JR; Pawsey, CC; Yiannikas, J, 1990) |
| "Metolazone and intravenous (IV) chlorothiazide are commonly used diuretics for sequential nephron blockade (SNB) in patients with acute decompensated heart failure (ADHF)." | 8.12 | Metolazone Versus Intravenous Chlorothiazide for Decompensated Heart Failure Sequential Nephron Blockade: A Retrospective Cohort Study. ( Biskupiak, J; Cisowska, T; Fang, JC; Jacobs, JA; Pan, IZ; Shah, KS, 2022) |
| "To assess the efficacy of intravenous chlorothiazide in patients with acute decompensated heart failure (ADHF) who were determined to be loop diuretic resistant and refractory to metolazone." | 7.83 | Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone. ( Altshuler, J; Cardinale, M; Testani, JM, 2016) |
| "To assess the efficacy and safety of intravenous (IV) chlorothiazide versus oral metolazone when added to loop diuretics in patients with acute decompensated heart failure (ADHF) and loop diuretic resistance." | 7.83 | Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. ( Devabhakthuni, S; Ivaturi, V; Jiang, A; Liu, T; Reed, BN; Shulenberger, CE, 2016) |
| "Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF)." | 7.79 | Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. ( Elkayam, U; Han, SY; Hshieh, S; Hyderi, AF; Jeng, AI; Kim, BJ; Konopka, E; Lou, M; Ng, TM; Phan, DH; Tsuji, Y, 2013) |
| "Metolazone-induced acute pancreatitis and hypercalcemia are described in a 58-year-old woman with severe congestive cardiac failure." | 7.68 | Case report: metolazone-associated hypercalcemia and acute pancreatitis. ( Anderson, PE; Austin, SM; Ellis, GG, 1991) |
| "Metolazone is a potent thiazide-like diuretic." | 6.71 | Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. ( Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005) |
| "Metolazone was as effective as chlorothiazide to augment loop diuretic therapy in ADHF in most studies with no pooled difference in net or total urine output." | 6.66 | A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure. ( Howard, ML; Janzen, KM; Steuber, TD, 2020) |
| "To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide." | 5.69 | Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. ( Brooksbank, KJM; Campbell, RT; Clark, AL; Docherty, KF; Foley, PWX; Guha, K; Halliday, CA; Jhund, PS; Kalra, PR; Lang, NN; Lee, MMY; McConnachie, A; McDermott, JJ; McKinley, G; McMurray, JJV; Osmanska, J; Petrie, MC; Platz, E; Sartipy, P; Seed, A; Stanley, B; Weir, RAP; Welsh, P; Yeoh, SE, 2023) |
| "Metolazone was strongly associated with hyponatremia, hypokalemia, and worsening renal function ( P<0." | 5.48 | Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis. ( Ahmad, T; Brisco-Bacik, MA; Houser, SR; Rao, V; Ter Maaten, JM; Testani, JM; Vedage, NA; Wilson, FP, 2018) |
| "To compare efficacy and safety of indapamide-furosemide combination against metolazone-furosemide combination in refractory heart failure patients." | 5.30 | Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial. ( Altaf, A; Jan, MU; Salahudin, M; Shah, H, 2019) |
| "Ten patients with severe congestive heart failure (6 women and 4 men, aged 67 +/- 4." | 5.27 | Combination of furosemide and metolazone in the treatment of severe congestive heart failure. ( Grosskopf, I; Rabinovitz, M; Rosenfeld, JB, 1986) |
| "Bendrofluazide and metolazone were equally effective in establishing a diuresis in patients with severe congestive cardiac failure resistant to loop diuretics." | 5.07 | Combination diuretic treatment in severe heart failure: a randomised controlled trial. ( Channer, KS; Lawson-Matthew, P; McLean, KA; Richardson, M, 1994) |
| "17 patients with New York Heart Association (NYHA) class IV congestive cardiac failure, refractory to conventional treatment, were additionally treated with oral metolazone (1." | 5.06 | Metolazone in treatment of severe refractory congestive cardiac failure. ( Arter, WJ; Field, MJ; Kiyingi, A; Lawrence, JR; Pawsey, CC; Yiannikas, J, 1990) |
| "Metolazone and intravenous (IV) chlorothiazide are commonly used diuretics for sequential nephron blockade (SNB) in patients with acute decompensated heart failure (ADHF)." | 4.12 | Metolazone Versus Intravenous Chlorothiazide for Decompensated Heart Failure Sequential Nephron Blockade: A Retrospective Cohort Study. ( Biskupiak, J; Cisowska, T; Fang, JC; Jacobs, JA; Pan, IZ; Shah, KS, 2022) |
| "To assess the efficacy of intravenous chlorothiazide in patients with acute decompensated heart failure (ADHF) who were determined to be loop diuretic resistant and refractory to metolazone." | 3.83 | Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone. ( Altshuler, J; Cardinale, M; Testani, JM, 2016) |
| "To assess the efficacy and safety of intravenous (IV) chlorothiazide versus oral metolazone when added to loop diuretics in patients with acute decompensated heart failure (ADHF) and loop diuretic resistance." | 3.83 | Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. ( Devabhakthuni, S; Ivaturi, V; Jiang, A; Liu, T; Reed, BN; Shulenberger, CE, 2016) |
| "Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF)." | 3.79 | Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. ( Elkayam, U; Han, SY; Hshieh, S; Hyderi, AF; Jeng, AI; Kim, BJ; Konopka, E; Lou, M; Ng, TM; Phan, DH; Tsuji, Y, 2013) |
| "Metolazone-induced acute pancreatitis and hypercalcemia are described in a 58-year-old woman with severe congestive cardiac failure." | 3.68 | Case report: metolazone-associated hypercalcemia and acute pancreatitis. ( Anderson, PE; Austin, SM; Ellis, GG, 1991) |
| "A patient with a history of diabetes mellitus and congestive heart failure was taking furosemide and metolazone as diuretics." | 3.67 | Alkalemia in diabetic ketoacidosis. ( Cronin, JW; Diamond, J; Kroop, SF; Rolla, AR, 1984) |
| "To evaluate efficacy of the association furosemide-metolazona in ten retrospective cases of Congestive heart failure, furosemide resistant." | 3.67 | [Metolazone in the treatment of refractory heart insufficiency. Experience of 10 cases]. ( Correia, JM; Loureiro, PA, 1989) |
| "In two patients with severe hypertension and moderately severe renal insufficiency, metolazone and furosemide were used in combination with propranolol, methyldopa, and hydralazine to augment control of blood pressure." | 3.66 | Severe electrolyte disturbances associated with metolazone and furosemide. ( Black, WD; Roman, J; Shiner, PT, 1978) |
| "Metolazone is a potent thiazide-like diuretic." | 2.71 | Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. ( Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005) |
| "Metolazone was as effective as chlorothiazide to augment loop diuretic therapy in ADHF in most studies with no pooled difference in net or total urine output." | 2.66 | A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure. ( Howard, ML; Janzen, KM; Steuber, TD, 2020) |
| "This metolazone emulsion was capable of increasing urine volume output and demonstrated both natriuretic and kaliuretic properties." | 1.72 | Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion. ( Ahlschwede, KM; Andey, T; Ofori, E; Osei, A; Somberg, JS, 2022) |
| "Metolazone was strongly associated with hyponatremia, hypokalemia, and worsening renal function ( P<0." | 1.48 | Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis. ( Ahmad, T; Brisco-Bacik, MA; Houser, SR; Rao, V; Ter Maaten, JM; Testani, JM; Vedage, NA; Wilson, FP, 2018) |
| "Ten patients with severe congestive heart failure (6 women and 4 men, aged 67 +/- 4." | 1.27 | Combination of furosemide and metolazone in the treatment of severe congestive heart failure. ( Grosskopf, I; Rabinovitz, M; Rosenfeld, JB, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (30.56) | 18.7374 |
| 1990's | 7 (19.44) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 7 (19.44) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlschwede, KM | 1 |
| Ofori, E | 1 |
| Andey, T | 1 |
| Osei, A | 1 |
| Somberg, JS | 1 |
| Cisowska, T | 1 |
| Pan, IZ | 1 |
| Biskupiak, J | 1 |
| Shah, KS | 1 |
| Fang, JC | 1 |
| Jacobs, JA | 1 |
| Au, HY | 1 |
| Chan, KY | 1 |
| Yap, DYH | 1 |
| Yip, T | 1 |
| Wong, CY | 1 |
| Yeoh, SE | 1 |
| Osmanska, J | 1 |
| Petrie, MC | 1 |
| Brooksbank, KJM | 1 |
| Clark, AL | 1 |
| Docherty, KF | 1 |
| Foley, PWX | 1 |
| Guha, K | 1 |
| Halliday, CA | 1 |
| Jhund, PS | 1 |
| Kalra, PR | 1 |
| McKinley, G | 1 |
| Lang, NN | 1 |
| Lee, MMY | 1 |
| McConnachie, A | 1 |
| McDermott, JJ | 1 |
| Platz, E | 1 |
| Sartipy, P | 1 |
| Seed, A | 1 |
| Stanley, B | 1 |
| Weir, RAP | 1 |
| Welsh, P | 1 |
| McMurray, JJV | 1 |
| Campbell, RT | 1 |
| Martens, P | 1 |
| Testani, J | 1 |
| Damman, K | 1 |
| Cox, ZL | 1 |
| Hung, R | 1 |
| Lenihan, DJ | 1 |
| Testani, JM | 3 |
| Salahudin, M | 1 |
| Shah, H | 1 |
| Jan, MU | 1 |
| Altaf, A | 1 |
| Steuber, TD | 1 |
| Janzen, KM | 1 |
| Howard, ML | 1 |
| Brisco-Bacik, MA | 1 |
| Ter Maaten, JM | 1 |
| Houser, SR | 1 |
| Vedage, NA | 1 |
| Rao, V | 1 |
| Ahmad, T | 1 |
| Wilson, FP | 1 |
| Ng, TM | 1 |
| Konopka, E | 1 |
| Hyderi, AF | 1 |
| Hshieh, S | 1 |
| Tsuji, Y | 1 |
| Kim, BJ | 1 |
| Han, SY | 1 |
| Phan, DH | 1 |
| Jeng, AI | 1 |
| Lou, M | 1 |
| Elkayam, U | 1 |
| Moranville, MP | 1 |
| Choi, S | 1 |
| Hogg, J | 1 |
| Anderson, AS | 1 |
| Rich, JD | 1 |
| Cardinale, M | 1 |
| Altshuler, J | 1 |
| Shulenberger, CE | 1 |
| Jiang, A | 1 |
| Devabhakthuni, S | 1 |
| Ivaturi, V | 1 |
| Liu, T | 1 |
| Reed, BN | 1 |
| Lee, DS | 1 |
| Lee, JS | 1 |
| Schull, MJ | 1 |
| Grimshaw, JM | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Rasmussen, ZZ | 1 |
| Barfod, T | 1 |
| Klit, J | 1 |
| Sparrow, N | 1 |
| Adlam, D | 1 |
| Cowley, A | 1 |
| Hampton, JR | 1 |
| Blue, L | 1 |
| McMurray, J | 1 |
| Rosenberg, J | 1 |
| Gustafsson, F | 1 |
| Galatius, S | 1 |
| Hildebrandt, PR | 1 |
| Weinrauch, LA | 1 |
| Belok, SS | 1 |
| Gauvin, GP | 1 |
| D'Elia, JA | 1 |
| Arosio, E | 1 |
| Pancera, P | 1 |
| Apolloni, E | 1 |
| Covi, G | 1 |
| Lechi, A | 1 |
| Cronin, JW | 1 |
| Kroop, SF | 1 |
| Diamond, J | 1 |
| Rolla, AR | 1 |
| Herbinger, W | 1 |
| Channer, KS | 1 |
| McLean, KA | 1 |
| Lawson-Matthew, P | 1 |
| Richardson, M | 1 |
| Broadley, AJ | 1 |
| Marshall, AJ | 1 |
| Sheth, UK | 1 |
| Mehta, JM | 1 |
| Paul, T | 1 |
| Nair, S | 1 |
| Sanghvi, B | 1 |
| Black, WD | 1 |
| Shiner, PT | 1 |
| Roman, J | 1 |
| Levey, BA | 1 |
| Palmer, RF | 1 |
| Kröger, N | 1 |
| Szuba, J | 1 |
| Frenzel, H | 1 |
| Anderson, PE | 1 |
| Ellis, GG | 1 |
| Austin, SM | 1 |
| Kiyingi, A | 1 |
| Field, MJ | 1 |
| Pawsey, CC | 1 |
| Yiannikas, J | 1 |
| Lawrence, JR | 1 |
| Arter, WJ | 1 |
| Farthing, D | 1 |
| Fakhry, I | 1 |
| Gehr, TW | 1 |
| Sica, DA | 1 |
| George, S | 1 |
| McBurney, A | 1 |
| Cole, A | 1 |
| Loureiro, PA | 1 |
| Correia, JM | 1 |
| Stevenson, LW | 1 |
| Dracup, KA | 1 |
| Tillisch, JH | 1 |
| Grosskopf, I | 1 |
| Rabinovitz, M | 1 |
| Rosenfeld, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure[NCT02606253] | Phase 4 | 60 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Investigation of the Diagnostic Accuracy of EHMRG Risk Score in Patients With Acute Heart Failure[NCT05710302] | 239 participants (Actual) | Observational | 2022-07-29 | Completed | |||
| Efficacy and Tolerability of Combination Intravenous Diuretic Therapy Versus Intravenous Loop Diuretic Therapy Alone for the Treatment of Acute Decompensated Heart Failure[NCT05840536] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn | ||
| Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing With Furosemide: a Pilot Study[NCT03746002] | Phase 4 | 3 participants (Actual) | Interventional | 2019-01-01 | Terminated (stopped due to Insufficient rate of patient enrollment/accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in estimated glomerular filtration rate (ml/min/m2) from baseline to 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | ml/min/m2 (Mean) |
|---|---|
| Metolazone | -6 |
| Chlorothiazide | -9 |
| Tolvaptan | 2 |
"Participants will score their congestion on a 10cm scale ranging from Best (10cm) to Worst (0cm). Change in score (units in centimeters) from baseline to 48 hours." (NCT02606253)
Timeframe: 48 hours
| Intervention | cm of dyspena analog scale (Median) |
|---|---|
| Metolazone | 4.0 |
| Chlorothiazide | 3.0 |
| Tolvaptan | 3.0 |
Change in serum chloride (mEq/L) from baseline to 48 hrs (NCT02606253)
Timeframe: 48 hours
| Intervention | mEq/L (Mean) |
|---|---|
| Metolazone | -7 |
| Chlorothiazide | -7 |
| Tolvaptan | 2 |
Diuretic Efficiency is calculated as 48hr urine output/ 48hr Furosemide equivalents in milligrams (NCT02606253)
Timeframe: 48 hours
| Intervention | UOP / 40mg IV furosemide (Mean) |
|---|---|
| Metolazone | 217 |
| Chlorothiazide | 294 |
| Tolvaptan | 326 |
Mean change in glomerular filtration rate from enrollment to end of study at hospital discharge, an average of 5 days (NCT02606253)
Timeframe: hospital discharge an average of 5 days
| Intervention | ml/min/m2 (Mean) |
|---|---|
| Metolazone | -2 |
| Chlorothiazide | -2 |
| Tolvaptan | -6 |
Mean change in serum creatinine (mg/dl) from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | mg/dl (Mean) |
|---|---|
| Metolazone | 0.3 |
| Chlorothiazide | 0.5 |
| Tolvaptan | 0.03 |
Mean change in serum potassium (mEq/L) from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | mEq/L (Mean) |
|---|---|
| Metolazone | -0.1 |
| Chlorothiazide | -0.2 |
| Tolvaptan | 0.1 |
Mean change in serum sodium (mEq/L) from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | mEq/L (Mean) |
|---|---|
| Metolazone | -1 |
| Chlorothiazide | -1 |
| Tolvaptan | 4 |
Net urine output from enrollment to the end of study at 48 hours measured in liters (NCT02606253)
Timeframe: 48 hours
| Intervention | liters (Median) |
|---|---|
| Metolazone | -7.8 |
| Chlorothiazide | -8.8 |
| Tolvaptan | -9.8 |
Incidence of new atrial or ventricular arrhythmias from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 0 |
| Chlorothiazide | 0 |
| Tolvaptan | 0 |
Provider escalation of loop diuretic dosage at 24 hours for urine output less than 3 L at 24 hours (NCT02606253)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 4 |
| Chlorothiazide | 4 |
| Tolvaptan | 2 |
Incidence of hypokalemia (serum potassium less than 3.5mEq/L ) from enrollment to end of study (NCT02606253)
Timeframe: 48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 3 |
| Chlorothiazide | 2 |
| Tolvaptan | 2 |
Incidence of death from study enrollment to hospital discharge, an average of 5 days (NCT02606253)
Timeframe: Enrollment to hospital discharge an average of 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 0 |
| Chlorothiazide | 0 |
| Tolvaptan | 0 |
Incidence of new initiation of dopamine, dobutamine, or milrinone from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 1 |
| Chlorothiazide | 0 |
| Tolvaptan | 2 |
Incidence of Renal replacement therapy utilization (hemodialysis, ultrafiltration) from enrollment to hospital discharge, an average of 5 days (NCT02606253)
Timeframe: enrollment to hospital discharge an average of 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 0 |
| Chlorothiazide | 0 |
| Tolvaptan | 0 |
SBP < 85 mmHg plus medical intervention for symptomatic hypotension (NCT02606253)
Timeframe: 48 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone | 2 |
| Chlorothiazide | 0 |
| Tolvaptan | 2 |
Cumulative dose of potassium supplementation (mEq) administered from enrollment to end of study at 48 hours (NCT02606253)
Timeframe: 48 hours
| Intervention | mEq (Mean) |
|---|---|
| Metolazone | 103 |
| Chlorothiazide | 63 |
| Tolvaptan | 58 |
The primary outcome will be 48-hour standing scale weight change (kg) from enrollment among the metolazone, intravenous chlorothiazide, and tolvaptan arms, using metolazone group as the comparator group for all other groups. (NCT02606253)
Timeframe: 48 hours
| Intervention | kg (Mean) |
|---|---|
| Metolazone | -4.6 |
| Chlorothiazide | -5.8 |
| Tolvaptan | -4.1 |
Total measured urine output in milliliters produced after metolazone dose is given (NCT03746002)
Timeframe: 24 hours
| Intervention | mL (Mean) |
|---|---|
| Metolazone Concurrent Dosing | 2030 |
| Metolazone Pre-dosing | 5650 |
Portion of patients with increase in serum creatinine by ≥ 0.3 mg/dL or ≥ 50% from baseline (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone Concurrent Dosing | 1 |
| Metolazone Pre-dosing | 1 |
Change in serum creatinine from baseline value collected prior to metolazone dose to value collected after metolazone dose (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose
| Intervention | mg/dL (Mean) |
|---|---|
| Metolazone Concurrent Dosing | 0.45 |
| Metolazone Pre-dosing | 0.38 |
Change in total body weight from baseline value measured prior to metolazone dose to value collected after metolazone dose (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose
| Intervention | kg (Mean) |
|---|---|
| Metolazone Concurrent Dosing | -.6 |
| Metolazone Pre-dosing | -8.5 |
Proportion of patients with potassium level less than 4.0 mEq/L measured after metolazone dose is given (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone Concurrent Dosing | 0 |
| Metolazone Pre-dosing | 1 |
Proportion of patients with magnesium level less than 2.0 mg/dL measured after metolazone dose is given (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone Concurrent Dosing | 0 |
| Metolazone Pre-dosing | 1 |
Proportion of patients with serum sodium level less than 135 mg/dL measured after metolazone dose is given (NCT03746002)
Timeframe: Baseline and at 12 to 23 hours after metolazone dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Metolazone Concurrent Dosing | 0 |
| Metolazone Pre-dosing | 0 |
2 reviews available for metolazone and Cardiac Failure
| Article | Year |
|---|---|
A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure.
Topics: Chlorothiazide; Diuretics; Heart Failure; Humans; Metolazone | 2020 |
How much responsibility should heart failure nurses take?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Comorbidit | 2005 |
6 trials available for metolazone and Cardiac Failure
| Article | Year |
|---|---|
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.
Topics: Diuretics; Furosemide; Heart Failure; Humans; Metolazone; Sodium; Sodium Potassium Chloride Symporte | 2023 |
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.
Topics: Administration, Oral; Aged; Chlorothiazide; Diuretics; Dose-Response Relationship, Drug; Double-Blin | 2020 |
Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Body Weight; Diuretics; Drug Therapy, Combi | 2019 |
Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Bumetanide; Diuretics; Drug Therapy, Combinati | 2005 |
Combination diuretic treatment in severe heart failure: a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bendroflumethiazide; Body Weight; Creatinine; Diuretics; | 1994 |
Metolazone in treatment of severe refractory congestive cardiac failure.
Topics: Aged; Aged, 80 and over; Body Weight; Clinical Trials as Topic; Diuresis; Diuretics; Dobutamine; Dru | 1990 |
28 other studies available for metolazone and Cardiac Failure
| Article | Year |
|---|---|
Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion.
Topics: Administration, Intravenous; Animals; Chlorothiazide; Diuretics; Emulsions; Heart Failure; Metolazon | 2022 |
Metolazone Versus Intravenous Chlorothiazide for Decompensated Heart Failure Sequential Nephron Blockade: A Retrospective Cohort Study.
Topics: Chlorothiazide; Diuretics; Furosemide; Heart Failure; Humans; Metolazone; Nephrons; Retrospective St | 2022 |
Topics: Conservative Treatment; Furosemide; Heart Failure; Humans; Kidney Failure, Chronic; Metolazone | 2023 |
Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?
Topics: Diuretics; Heart Failure; Humans; Metolazone; Sodium Potassium Chloride Symporter Inhibitors | 2023 |
Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
Topics: Acute Disease; Aged; Cause of Death; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gu | 2018 |
Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.
Topics: Acute Disease; Adult; Aged; Blood Urea Nitrogen; Bumetanide; Cohort Studies; Diuretics; Drug Therapy | 2013 |
Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Aged; Chicago; Chlorothiazide; Dru | 2015 |
Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone.
Topics: Acute Disease; Administration, Intravenous; Adult; Aged; Chlorothiazide; Diuretics; Female; Heart Fa | 2016 |
Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Aged; Chlorothiazide; Cohor | 2016 |
Design and rationale for the Acute Congestive Heart Failure Urgent Care Evaluation: The ACUTE Study.
Topics: Age Factors; Algorithms; Ambulances; Antihypertensive Agents; Blood Pressure; Comorbidity; Creatinin | 2016 |
[Renal effect of treatment for heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Diuretics; Furosemide; Heart Failure; Hu | 2009 |
Difficulties of introducing the National Service Framework for heart failure into general practice in the UK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Di | 2003 |
Palpable acute necrotizing arteritis secondary to metolazone.
Topics: Aged; Diuretics; Drug Hypersensitivity; Female; Heart Failure; Humans; Metolazone; Polyarteritis Nod | 1982 |
[Clinical evaluation of metolazone in edematogenic syndromes].
Topics: Adult; Aged; Coronary Disease; Diuretics; Edema; Female; Heart Failure; Heart Valve Diseases; Humans | 1984 |
Alkalemia in diabetic ketoacidosis.
Topics: Aged; Alkalosis; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Diuretics; Female; Furosemide; He | 1984 |
[Diuretics in the therapy of chronic cardiac insufficiency].
Topics: Acetazolamide; Amiloride; Diuretics; Drug Interactions; Ethacrynic Acid; Heart Failure; Humans; Inda | 1982 |
Self administration of metolzaone reduces readmissions with decompensated congestive cardiac failure.
Topics: Aged; Diuretics; Female; Heart Failure; Humans; Male; Metolazone; Middle Aged; Self Administration | 1999 |
Clinical experience with metolazone--a new diuretic--in cases of edema and ascites due to hepatic cirrhosis, C.C.F., and malnutrition.
Topics: Adult; Diuretics; Edema; Heart Failure; Humans; Liver Cirrhosis; Male; Metolazone; Nutrition Disorde | 1977 |
Severe electrolyte disturbances associated with metolazone and furosemide.
Topics: Adult; Aged; Diuretics; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hypert | 1978 |
Biochemical and clinical effects of metolazone in congestive heart failure.
Topics: Aged; Alkaline Phosphatase; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; Calcium; Creatinine; | 1975 |
[Metolazone in the treatment of advanced therapy-resistant dilated cardiomyopathy].
Topics: Aged; Aged, 80 and over; Cardiomyopathy, Dilated; Drug Therapy, Combination; Edema, Cardiac; Female; | 1991 |
Case report: metolazone-associated hypercalcemia and acute pancreatitis.
Topics: Acute Disease; Female; Heart Failure; Humans; Hypercalcemia; Hypertension; Metolazone; Middle Aged; | 1991 |
Quantitation of metolazone in urine by high-performance liquid chromatography with fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Heart Failure; Humans; Male; Metolazone; Natriuresis; Sensitiv | 1990 |
Possible protein binding displacement interaction between glibenclamide and metolazone.
Topics: Aged; Binding, Competitive; Blood Proteins; Dialysis; Diuretics; Glyburide; Heart Failure; Humans; H | 1990 |
Oral metolazone plus frusemide for home therapy in patients with refractory heart failure.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Diuretics; Drug Evaluation; Drug Therapy, Combin | 1989 |
[Metolazone in the treatment of refractory heart insufficiency. Experience of 10 cases].
Topics: Aged; Diuresis; Diuretics; Drug Evaluation; Drug Therapy, Combination; Female; Furosemide; Heart Fai | 1989 |
Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Cardiovascular Agents; Combined Modality Therapy; Drug | 1989 |
Combination of furosemide and metolazone in the treatment of severe congestive heart failure.
Topics: Aged; Body Weight; Diuretics; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; | 1986 |